Phase 2 Study to Evaluate Safety and Immune Response of mRNA Flu Vaccines in Adults 18 and Older

What this Trial Is About

Researchers are evaluating the safety and immune response of several mRNA-based influenza vaccines in healthy adults aged 18 years and older. This Phase 2, randomized, double-blind study compares six investigational mRNA flu vaccines against licensed influenza vaccines. The goal is to understand how well these vaccines stimulate the bodys defense against the flu virus and to monitor any side effects. Participants will receive one single dose of either one of the six mRNA influenza vaccine candidates or one of the licensed flu vaccines by intramuscular injection on Day 1. The study includes one treatment period where the vaccines are administered, and the participants will be monitored for reactions and immune responses over time. Participants will visit the study site at least three times over approximately six months. At each visit, blood samples will be collected to measure antibody levels, and a nasal swab will be taken at the first visit. Researchers will track local and systemic reactions within 7 days of vaccination, as well as adverse events, serious adverse events, and any new chronic medical conditions for up to six months. The study aims to assess the immune response and safety profile of the vaccines during this period.

A Study to Learn About mRNA Vaccines Against Influenza in Adults